Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Assessing cardiovascular disease (CVD) in children with chronic kidney disease (CKD) is difficult. Great expectations have been associated with biomarkers, including the N-terminal pro-brain natriuretic peptide (NT-proBNP). This study aimed to determine the correlation between NT-proBNP and cardiovascular complications in children with CKD. Serum NT-proBNP, arterial stiffness, common carotid artery intima-media thickness (cIMT), echocardiographic (ECHO) parameters (including tissue Doppler imaging), and biochemical and clinical data were analyzed in 38 pediatric patients with CKD (21 boys, 12.2 ± 4.2 years). Mean NT-proBNP in CKD patients was 1068.1 ± 4630 pg/mL. NT-proBNP above the norm (125 pg/mL) was found in 16 (42.1%) subjects. NT-proBNP correlated with glomerular filtration rate (GFR) (r = -0.423, = 0.008), and was significantly higher in CKD G5 (glomerular filtration rate grade) patients compared to CKD G2, G3, and G4 children ( = 0.010, = 0.004, and = 0.018, respectively). Moreover, NT-proBNP correlated positively with augmentation index (AP/PP: r = 0.451, = 0.018, P2/P: r = 0.460, = 0.016), cIMT (r = 0.504, = 0.020), and E/E' in ECHO (r = 0.400, = 0.032). In multivariate analysis, logNT-proBNP was the only significant predictor of cIMT Z-score (beta = 0.402, 95CI (0.082-0.721), = 0.014) and P2/P1 (beta = 0.130, 95CI (0.082-0.721), = 0.014). Conclusions: NT-proBNP may serve as a possible marker of thickening of the carotid artery wall in pediatric patients with CKD. The final role of NT-proBNP as a biomarker of arterial damage, left ventricular hypertrophy, or cardiac diastolic dysfunction in CKD children needs confirmation in prospective studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509500 | PMC |
| http://dx.doi.org/10.3390/jcm10194344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Impaired Pulmonary Vascular Reserve in Adults with Repaired Coarctation of Aorta: Prevalence, Correlates, and Association with Disease Severity.
J Am Soc Echocardiogr
September 2025
From the Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55905.
Background: Pulmonary hypertension is associated with cardiovascular events, but when assessed at rest, it has limited sensitivity. Pulmonary vascular reserve can be assessed noninvasively using exercise echocardiography, but this has not been studied in adults with coarctation of aorta (COA). We hypothesized that adults with COA had worse pulmonary vascular reserve compared to controls, and that impaired pulmonary vascular reserve was associated with clinical indices of disease severity independent right ventricular (RV) indices at rest.
View Article and Find Full Text PDFImmunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.
Future Sci OA
December 2025
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Background: Smoking induces inflammation in the heart and intima layer of blood vessels by activating nuclear factor kappa B, which controls the transcription of immunoglobulin free light chain (FLC)-κ. FLC levels are indicative of higher mortality in the overall population and poorer prognoses in cardiovascular diseases. This study aimed to analyze the effect of smoking cessation (SC) on the levels of FLCs and markers of inflammation and heart failure.
View Article and Find Full Text PDFBiomarker-based pre-heart failure screening in a middle-aged rural population.
J Cardiol
September 2025
Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Epidemiology, Disease Control, and Prevention, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. Electronic address:
Background: Guidelines recommend biomarker-based screening for pre-heart failure (pre-HF) among at-risk populations. Although the asymptomatic nature of pre-HF necessitates proactive screening, real-world implementation remains understudied. This retrospective study analyzed data from a regional pre-HF screening initiative, integrated into annual health screenings, to evaluate: (1) the prevalence of elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, (2) associated echocardiographic findings, and (3) adherence across the screening-to-consultation pathway.
View Article and Find Full Text PDFCurrent Practices for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension in Neonates: A Survey Study in Spain.
Pediatr Pulmonol
September 2025
Department of Neonatology, La Paz University Hospital, Madrid, Spain.
Objective: To describe national patterns in the screening, diagnosis, and clinical management of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) in Spanish neonatal intensive care units (NICUs) and assess the need for standardized screening and management protocols and unified follow-up strategies.
Methods: A 20-question electronic survey was distributed to all Level III NICUs in the Spanish public health system to evaluate practices in BPD-PH screening, diagnosis, and clinical management. Results were analyzed globally and by NICU level (IIIB vs.